Payment overview · 2025
General Payments
$52.06
3 reported records · 2 companies
Healthcare provider profile · identity verified
Matthew L West, MD
Allopathic & Osteopathic Physicians|Family Medicine · BARTLESVILLE, OK · NPI 1508884313
Verified facts
What the public records show
CMS Open Payments records show Matthew L West, MD received $52.06 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 69.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.96 | 69.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.10 | 30.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.06 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 562 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 164 |
| Gabapentin | Gabapentin | 547 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 504 | 100 |
| Omeprazole | Omeprazole | 493 | 133 |
| Losartan Potassium | Losartan Potassium | 454 | 128 |
| Duloxetine Hcl | Duloxetine Hcl | 448 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 104 |
| Lisinopril | Lisinopril | 363 | 107 |
| Metformin Hcl | Metformin Hcl | 354 | 103 |
| Tramadol Hcl | Tramadol Hcl | 281 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 62 |
| Potassium Chloride | Potassium Chloride | 265 | 78 |
| Simvastatin | Simvastatin | 257 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 72 |
| Farxiga | Dapagliflozin Propanediol | 222 | 40 |
| Meloxicam | Meloxicam | 211 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 58 |
| Montelukast Sodium | Montelukast Sodium | 188 | 53 |
| Celecoxib | Celecoxib | 183 | 45 |
| Trazodone Hcl | Trazodone Hcl | 168 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 46 |
| Furosemide | Furosemide | 160 | 52 |
| Buspirone Hcl | Buspirone Hcl | 155 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 51 |
| Carvedilol | Carvedilol | 145 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 38 |
| Metformin Hcl Er | Metformin Hcl | 136 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 24 |
| Alprazolam | Alprazolam | 132 | 30 |
| Allopurinol | Allopurinol | 129 | 33 |
| Sertraline Hcl | Sertraline Hcl | 129 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 128 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 45 |
| Pregabalin | Pregabalin | 119 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 33 |
| Mounjaro | Tirzepatide | 116 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 28 |
| Finasteride | Finasteride | 103 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 30 |
| Bupropion Xl | Bupropion Hcl | 101 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 23 |
| Ozempic | Semaglutide | 95 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 22 |
| Donepezil Hcl | Donepezil Hcl | 90 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 25 |
| Eliquis | Apixaban | 87 | 22 |
| Trulicity | Dulaglutide | 83 | 22 |
| Atenolol | Atenolol | 82 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 25 |
| Mirtazapine | Mirtazapine | 81 | 16 |
| Lorazepam | Lorazepam | 76 | 21 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 18 |
| Glipizide | Glipizide | 73 | 24 |
| Enalapril Maleate | Enalapril Maleate | 72 | 21 |
| Tradjenta | Linagliptin | 68 | 14 |
| Benazepril Hcl | Benazepril Hcl | 65 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | suppressed |
| Estradiol | Estradiol | 60 | 17 |
| Synthroid | Levothyroxine Sodium | 60 | 17 |
| Januvia | Sitagliptin Phosphate | 59 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 16 |
| Spironolactone | Spironolactone | 56 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 17 |
| Fenofibrate | Fenofibrate | 55 | 15 |
| Propranolol Hcl | Propranolol Hcl | 55 | 12 |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Clonazepam | Clonazepam | 52 | 12 |
| Ondansetron Odt | Ondansetron | 52 | 22 |
| Jardiance | Empagliflozin | 50 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 15 |
| Famotidine | Famotidine | 48 | 15 |
| Diazepam | Diazepam | 47 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 45 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 21 |
| Temazepam | Temazepam | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Risperidone | Risperidone | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Baclofen | Baclofen | 38 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 14 |
| Valsartan | Valsartan | 35 | 14 |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Testosterone | Testosterone | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Belsomra | Suvorexant | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Metformin Er Osmotic | Metformin Hcl | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Clonidine | Clonidine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.06 · 3 records | Novo Nordisk Inc | EVENITY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error